Home » Our story



Diabetic foot ulcers have a debilitating impact on patients. Despite numerous treatment options, about 60% of all patients experience a wound that does not heal.46 If the severity of a wound progresses to grade 4 or 5, the cost of treatment is eight times higher than a grade 1 or 2 wound.47 For about 20% of patients, treatment ends in amputation within one year.48

At Reapplix, we have established that one of the keys to successful wound treatment lies in the body’s capacity to heal – and each patient is central to that process. Using just a small sample of the patient’s blood – nothing else – the 3C Patch® System separates, coagulates and compacts the blood components into a solid patch. The result is a single 3C Patch® comprising a concentration of proteins, active cells and growth factors.

Each 3C Patch® takes about 20 minutes to produce and is applied directly to the wound at point-of-care. One of few evidence-based wound treatments, the 3C Patch® is clinically proven to significantly accelerate wound healing of hard-to-heal diabetic foot ulcers.1 The outcome is a cost-effective, personalized wound treatment that draws on each patient’s unique ability to help their own healing process.

Every wound is personal.

Niels Erik Holm, Reapplix’s co-founder also invented the NovoLet pen, which has helped millions of diabetic patients all over the world since its introduction in the 1980s. Photo: Scanpix
“Every 20 seconds somewhere in the world someone loses a leg due to the complications of diabetes. At this moment, millions of people with diabetes suffer from poorly healing foot ulcers. These people can be helped when a multidisciplinary foot team shares common goals and follows evidence-based care.”

International Working Group on the Diabetic Foot45